Diucifonum treatment of patients with systemic scleroderma

R. Sh. Abdrakhmanova; Абдрахманова Р. Ш.; I. L. Bilich; Билич И. Л.; M. M. Mangusheva; Мангушева М. М.; L. K. Bombina; Бомбина Л. К.; G. M. Khalfieva; Халфиева Г. М.

doi:10.17816/kazmj65308

Diucifonum treatment of patients with systemic scleroderma

Authors: Abdrakhmanova R.S.¹, Bilich I.L.¹, Mangusheva M.M.¹, Bombina L.K.¹, Khalfieva G.M.¹
Affiliations:
1. S.V. Kurashov Kazan Medical Institute
Issue: Vol 67, No 2 (1986)
Pages: 96-98
Section: Articles
URL: https://journals.rcsi.science/kazanmedj/article/view/65308
DOI: https://doi.org/10.17816/kazmj65308
ID: 65308

Cite item

Full Text

Abstract
Full Text
About the authors
References
Statistics

Abstract

The treatment of patients with systemic scleroderma is still a challenging task for internal medicine clinics. This paper presents the results of the therapeutic efficacy of diucciphone in such patients at different periods of observation. Diucciphone (2,4 dioxo-6-methylpyrimidinyl-5-sulfonoamido)-diphenylsulfone is an antileprosy drug synthesized at the A.E. Arbuzov Institute of Organic and Physical Chemistry, KFAN of the USSR.